Popular Articles

Boehringer Ingelheim To Commence Phase III Study Investigating BIBW 2992 As Treatment For Non-Small Cell Lung Cancer Patients With EGFR Mutations
Boehringer Ingelheim announced today at the International Association for the Study of Lung Cancer"s 13th World Conference on Lung Cancer (WCLC), San Francisco, CA, the initiation of a Phase III clinical study of BIBW 2992 as first-line treatment in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. BIBW 2992 (planned brand name Tovok™) is the first orally-administered, irreversible dual inhibitor of EGFR and HER2,1 to reach Phase III development in NSCLC.2
generic viagra online
Cancer Research Partnership Between UCSF, MMRF To Drive Drug Development
The University of California, San Francisco (UCSF) and the Multiple Myeloma Research Foundation (MMRF) have established the Stephen and Nancy Grand Multiple Myeloma Translational Initiative, a research collaboration dedicated to translating basic science discoveries into new candidate drugs for testing in clinical trials.
News of the day
Celleron Therapeutics And Astrazeneca Announce Personalised Medicine Collaboration In Cancer For The Development Of AZ's Leading HDAC Inhibitor
Celleron Therapeutics Ltd, the Oxford UK based specialist in the development of individually targeted cancer medicines, has secured exclusive rights to AstraZeneca plc"s lead histone deacetylase (HDAC) inhibitor (AZD 9468), for global development in conjunction with its proprietary "CancerNav" predictive biomarker platform. "CancerNav" specifically identifies those tumours which are most likely to respond to an individual cancer drug, thereby enabling a highly focussed clinical development and commercialisation programme, based on a closely linked diagnostic and therapeutic "personalised medicine" approach.
Cardiovascular

Even Mildly Abnormal Blood Sugar Levels During Pregnancy Increases Risk Of Developing Type 2 Diabetes

Gestational diabetes happens in more than three per cent of pregnancies in Ontario. Usually the condition resolves itself after delivery, but many studies have shown that these women are at a very high risk for developing "regular" type 2 diabetes later in life. New research out of the Institute for Clinical Evaluative Sciences (ICES) has found that even women with mild abnormalities in their blood sugar during pregnancy, previously thought not to have any clinical significance, are 2.5 times more likely to develop type 2 diabetes compared to those who had completely normal glucose testing. * To test for gestational diabetes, women receive a glucose challenge test (GCT) in the late second trimester of pregnancy. If the result of this test is abnormal, they go on to have a diagnostic test, called the oral glucose tolerance test (OGTT). If this test does not show gestational diabetes, women are reassured their glucose levels are normal and that no further testing is needed. * However, recent studies have suggested that women who have even mild abnormalities on either the GCT or the OGTT do actually have subtle differences in their metabolism after pregnancy. * The study examined 15,000 pregnant women aged 20-49 in Ontario who had a mild abnormality on their GCT but did not ultimately get diagnosed with gestational diabetes. They were compared to about 60,000 pregnant women who did not have abnormalities on their GCT. The women were followed for 6.4 years after delivery, and those who had had an abnormal GCT were 2.5 times more likely to develop type 2 diabetes compared to those who had not had an abnormal GCT. "These results show that even a mild abnormality in glucose testing during pregnancy is associated with an increased risk of diabetes later in life. Although we already know that women who"ve had gestational diabetes need to be monitored, the study suggests that even women with mild glucose abnormalities might benefit from diabetes prevention and detection strategies," says Baiju Shah, ICES researcher. Author affiliations: ICES (Shah), Mount Sinai Hospital (Retnakaran), Sunnybrook Health Sciences Centre (Shah); Ontario. The study "Abnormal Screening Glucose Challenge Test in Pregnancy and Future Risk of Diabetes in Young Women" is in the May, 2009 issue of Diabetic Medicine. Deborah Creatura Institute for Clinical Evaluative Sciences


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):